These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29108879)

  • 1. Remyelination modulators in multiple sclerosis patients.
    Al-Temaimi R; AbuBaker J; Al-Khairi I; Alroughani R
    Exp Mol Pathol; 2017 Dec; 103(3):237-241. PubMed ID: 29108879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis.
    Khalil M; Renner A; Langkammer C; Enzinger C; Ropele S; Stojakovic T; Scharnagl H; Bachmaier G; Pichler A; Archelos JJ; Fuchs S; Seifert-Held T; Fazekas F
    Mult Scler; 2016 Oct; 22(12):1560-1568. PubMed ID: 26762671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.
    Al Nimer F; Elliott C; Bergman J; Khademi M; Dring AM; Aeinehband S; Bergenheim T; Romme Christensen J; Sellebjerg F; Svenningsson A; Linington C; Olsson T; Piehl F
    Neurol Neuroimmunol Neuroinflamm; 2016 Feb; 3(1):e191. PubMed ID: 26770997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse.
    Frota ER; Rodrigues DH; Donadi EA; Brum DG; Maciel DR; Teixeira AL
    Neurosci Lett; 2009 Aug; 460(2):130-2. PubMed ID: 19477225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
    Piehl F; Kockum I; Khademi M; Blennow K; Lycke J; Zetterberg H; Olsson T
    Mult Scler; 2018 Jul; 24(8):1046-1054. PubMed ID: 28627962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
    Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
    Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report.
    Văcăraş V; Major ZZ; Buzoianu AD
    Neurol Neurochir Pol; 2017; 51(3):221-226. PubMed ID: 28392137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurofilament protein light in multiple sclerosis].
    Zhang Y; Li X; Qiao J
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2745-9. PubMed ID: 18167263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
    Tortorella C; Direnzo V; Ruggieri M; Zoccolella S; Mastrapasqua M; D'Onghia M; Paolicelli D; Cuonzo FD; Gasperini C; Trojano M
    Mult Scler; 2018 Jul; 24(8):1039-1045. PubMed ID: 28537100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light chain level is a weak risk factor for the development of MS.
    Arrambide G; Espejo C; Eixarch H; Villar LM; Alvarez-Cermeño JC; Picón C; Kuhle J; Disanto G; Kappos L; Sastre-Garriga J; Pareto D; Simon E; Comabella M; Río J; Nos C; Tur C; Castilló J; Vidal-Jordana A; Galán I; Arévalo MJ; Auger C; Rovira A; Montalban X; Tintore M
    Neurology; 2016 Sep; 87(11):1076-84. PubMed ID: 27521440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis.
    Golan M; Mausner-Fainberg K; Ibrahim B; Benhamou M; Wilf-Yarkoni A; Kolb H; Regev K; Karni A
    CNS Drugs; 2019 Dec; 33(12):1229-1237. PubMed ID: 31713782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients.
    Gresle MM; Liu Y; Dagley LF; Haartsen J; Pearson F; Purcell AW; Laverick L; Petzold A; Lucas RM; Van der Walt A; Prime H; Morris DR; Taylor BV; ; Shaw G; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1209-13. PubMed ID: 24639436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of plasma brain-derived neurotrophic factor (BDNF), activity-dependent neurotrophin protein (ADNP) and vasoactive intestinal peptide (VIP) concentrations in treatment-naïve humans with multiple sclerosis.
    Kochanowski J; Uchman D; Litwiniuk A; Kalisz M; Wolinska-Witort E; Martynska L; Baranowska B; Bik W
    Neuro Endocrinol Lett; 2015; 36(2):148-52. PubMed ID: 26071584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.
    Disanto G; Adiutori R; Dobson R; Martinelli V; Dalla Costa G; Runia T; Evdoshenko E; Thouvenot E; Trojano M; Norgren N; Teunissen C; Kappos L; Giovannoni G; Kuhle J;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):126-9. PubMed ID: 25716934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
    Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
    J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of brain-derived neurotrophic factor in patients with multiple sclerosis.
    Naegelin Y; Saeuberli K; Schaedelin S; Dingsdale H; Magon S; Baranzini S; Amann M; Parmar K; Tsagkas C; Calabrese P; Penner IK; Kappos L; Barde YA
    Ann Clin Transl Neurol; 2020 Nov; 7(11):2251-2261. PubMed ID: 33031634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain derived neurotrophic factor in multiple sclerosis: effect of 24 weeks endurance and resistance training.
    Wens I; Keytsman C; Deckx N; Cools N; Dalgas U; Eijnde BO
    Eur J Neurol; 2016 Jun; 23(6):1028-35. PubMed ID: 26992038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.